Abstract:The current 'fixed-dosage strategy' approach to medicine, means there is much inter-individual variation in drug response. Pharmacogenetics is the study of how inter-individual variations in the DNA sequence of specific genes affect drug responses. This article will highlight current pharmacogenetic knowledge on important drug metabolizing enzymes, drug transporters and drug targets to understand interindividual variability in drug clearance and responses in clinical practice and potential use in personalized medicine. Polymorphisms in the cytochrome P450 (CYP) family may have had the most impact on the fate of pharmaceutical drugs. CYP2D6, CYP2C19 and CYP2C9 gene polymorphisms and gene duplications account for the most frequent variations in phase I metabolism of drugs since nearly 80% of drugs in use today are metabolised by these enzymes. Approximately 5% of Europeans and 1% of Asians lack CYP2D6 activity, and these individuals are known as poor metabolizers. CYP2C9 is another clinically significant drug metabolising enzyme that demonstrates genetic variants. Studies into CYP2C9 polymorphism have highlighted the importance of the CYP2C9*2 and CYP2C9*3 alleles. Extensive polymorphism also occurs in a majority of Phase II drug metabolizing enzymes. One of the most important polymorphisms is thiopurine S-methyl transferases (TPMT) that catalyzes the S-methylation of thiopurine drugs. With respect to drug transport polymorphism, the most extensively studied drug transporter is P-glycoprotein (P-gp/MDR1), but the current data on the clinical impact is limited. Polymorphisms in drug transporters may change drug's distribution, excretion and response. Recent advances in molecular research have revealed many of the genes that encode drug targets demonstrate genetic polymorphism. These variations, in many cases, have altered the targets sensitivity to the specific drug molecule and thus have a profound effect on drug efficacy and toxicity. For example, the beta (2)-adrenoreceptor, which is encoded by the ADRB2 gene, illustrates a clinically significant genetic variation in drug targets. The variable number tandem repeat polymorphisms in serotonin transporter (SERT/SLC6A4) gene are associated with response to antidepressants. The distribution of the common variant alleles of genes that encode drug metabolizing enzymes, drug transporters and drug targets has been found to vary among different populations. The promise of pharmacogenetics lies in its potential to identify the right drug at the right dose for the right individual. Drugs with a narrow therapeutic index are thought to benefit more from pharmacogenetic studies. For example, warfarin serves as a good practical example of how pharmacogenetics can be utilized prior to commencement of therapy in order to achieve maximum efficacy and minimum toxicity. As such, pharmacogenetics has the potential to achieve optimal quality use of medicines, and to improve the efficacy and safety of both prospective and licensed drugs.

Characterizing the genetic architecture of drug response using gene-context interaction methods

Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medications

State-of-the-Art Technologies to Interrogate Genetic/Genomic Components of Drug Response

Deciphering Genetic Influence on Drug Response

Strategies to Identify Pharmacogenomic Biomarkers: Candidate Gene, Pathway-Based, and Genome-Wide Approaches

Pharmacogenomic profile of a central European urban random population-Czech population

Promises and challenges in pharmacoepigenetics

A Genetic Analysis of Current Medication Use in the UK Biobank

Utilizing Large Electronic Medical Record Data Sets to Identify Novel Drug–Gene Interactions for Commonly Used Drugs

Impact of New Genomic Technologies on Understanding Adverse Drug Reactions

Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population

Clinical Pharmacogenetics and Potential Application in Personalized Medicine.

Clinical Utility and Implementation of Pharmacogenomics for the Personalisation of Antipsychotic Treatments

Genetic variation in human drug-related genes

Combining Genetic Proxies of Drug Targets and Time-to-event analyses From Longitudinal Observational Data To Identify Target Patient Populations

Pharmacogenomics: current status and future perspectives

The impact on clinical success from the 23andMe cohort

Genome-wide meta-analyses of non-response to antidepressants identify novel loci and potential drugs

Leveraging the Genetics of Psychiatric Disorders to Prioritize Potential Drug Targets and Compounds

Robust use of phenotypic heterogeneity at drug target genes for mechanistic insights: Application of cis‐multivariable Mendelian randomization to GLP1R gene region

Assessment of Pharmacogenomic Agreement.